Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.43 |
| ▸ | DHFR | P00374 | 1/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 9/20 | 0.39 |
| ▸ | ADRA2B | P18089 | 7/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 7/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.39 |
| ▸ | CFB | P00751 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.34 |
| ▸ | CLCN2 | P51788 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7045608 | 0.86 | TAAR1 (0.46) | TAAR1ADRA2AADRA2BADRA2CADRA1A | |
| SCHEMBL7048853 | 0.86 | TAAR1 (0.52) | TAAR1ADRA2AADRA2BADRA2CADRA1A | |
| SCHEMBL9788292 | 0.84 | TAAR1 (0.42) | TAAR1ADRA2AADRA2BADRA2CADRA1A | |
| SCHEMBL9559073 | 0.77 | ADRA2A (0.47) | TAAR1ADRA2AADRA2BADRA2CADRA1A | |
| SCHEMBL9788302 | 0.77 | TAAR1 (0.40) | TAAR1ADRA2AADRA2BADRA2CADRA1A | |
| SCHEMBL29196078 | 0.76 | DHFR (0.50) | TAAR1DHFRKCNH2SCN5ACLCN2 | |
| SCHEMBL9788279 | 0.75 | TAAR1 (0.41) | TAAR1ADRA2AADRA2BADRA2CADRA1A | |
| SCHEMBL9788281 | 0.75 | ADRA2A (0.40) | TAAR1ADRA2AADRA2BADRA2CADRA1A | |
| SCHEMBL9788271 | 0.73 | TNIK (0.45) | TAAR1ADRA2AADRA2BADRA2CADRA1A | |
| SCHEMBL7046036 | 0.73 | TAAR1 (0.57) | TAAR1DHFRADRA2AADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0724439-B1 | USE OF 2-(2ALKYLPHENYLAMINO)OXAZOLINES AND -THIAZOLINES FOR THE MANUFACTURE OF A MEDICAMENT WITH ALPHA 2 ADRENERGIC EFFECT | ALLERGAN SALES INC (US) | 2003-04-09 | — | — | EP | disclosed |
| US-5708015-A | SENSITIVE ALPHA 2 ADRENERGIC RECEPTORS | ALLERGAN (US) | 1998-01-13 | — | — | US | disclosed |
| US-5580892-A | ANTIDIARRHETIC, ANTISPASTIC, ANTIEPILEPTIC AGENTS; DIURETICS | ALLERGAN | 1996-12-03 | — | — | US | disclosed |
| EP-0724439-A1 | USE OF 2-(2-ALKYLPHENYLAMINO)-OXAZOLINES, -THIAZOLINES AND -IMIDAZOLINES AS ALPHA 2 ADRENERGIC AGENTS | Allergan (US) | 1996-08-07 | — | — | EP | disclosed |
| WO-1995011021-A1 | USE OF 2-(2-ALKYLPHENYLAMINO)-OXAZOLINES, -THIAZOLINES AND -IMIDAZOLINES AS ALPHA 2 ADRENERGIC AGENTS | ALLERGAN (US) | 1995-04-27 | — | — | WO | disclosed |
| US-5252595-A | Method for reducing or maintaining intraocular pressure in the mammalian eye by administering pharmaceutical compositions containing 2-(2-alkylphenylamino)-oxazolines, 2-(2-alkylphenylamino)-thiazolines and 2-(2-alkylphenylamino)-imidazolines | ALLERGAN, INC. (US) | 1993-10-12 | — | — | US | disclosed |
| US-5151440-A | Treatment of glaucoma | ALLERGAN, INC. (US) | 1992-09-29 | — | — | US | disclosed |